Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. Keeping that in mind, here is one stock likely to meet or exceed Wall Street’s lofty expectations and two where its enthusiasm might be excessive.
Two Stocks to Sell:
Fiverr (FVRR)
Consensus Price Target: $16 (46.8% implied return)
Based in Tel Aviv, Fiverr (NYSE: FVRR) operates a fixed price global freelance marketplace for digital services.
Why Is FVRR Not Exciting?
- Intense competition is diverting traffic from its platform as its active buyers fell by 11% annually
- Projected sales decline of 6.4% for the next 12 months points to a tough demand environment ahead
- Expensive marketing campaigns hurt its profitability and make us wonder what would happen if it let up on the gas
Fiverr’s stock price of $10.90 implies a valuation ratio of 1.2x forward price-to-gross profit. To fully understand why you should be careful with FVRR, check out our full research report (it’s free).
CoreCivic (CXW)
Consensus Price Target: $29.80 (44.7% implied return)
Originally founded in 1983 as the first private prison company in the United States, CoreCivic (NYSE: CXW) operates correctional facilities, detention centers, and residential reentry programs for government agencies across the United States.
Why Do We Think Twice About CXW?
- 3% annual revenue growth over the last five years was slower than its business services peers
- Efficiency has decreased over the last five years as its adjusted operating margin fell by 4.7 percentage points
- Free cash flow margin dropped by 7.3 percentage points over the last five years, implying the company became more capital intensive as competition picked up
CoreCivic is trading at $20.60 per share, or 12.7x forward P/E. If you’re considering CXW for your portfolio, see our FREE research report to learn more.
One Stock to Watch:
Halozyme Therapeutics (HALO)
Consensus Price Target: $85.22 (22.3% implied return)
Known for transforming hours-long intravenous infusions into minutes-long subcutaneous injections, Halozyme Therapeutics (NASDAQ: HALO) develops and licenses its proprietary ENHANZE technology that enables subcutaneous delivery of injectable drugs that would otherwise require intravenous administration.
Why Are We Fans of HALO?
- Annual revenue growth of 39.2% over the last five years was superb and indicates its market share increased during this cycle
- Market share will likely rise over the next 12 months as its expected revenue growth of 26.1% is robust
- Earnings per share have massively outperformed its peers over the last five years, increasing by 35.6% annually
At $69.66 per share, Halozyme Therapeutics trades at 8.6x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
